Peptides BiosciencesRetatrutide 20mg + Cagrilintide 5mg blend 25mg
Retatrutide combined with Cagrilintide is an advanced peptide therapy researched for its potential benefits in weight management, appetite control, and metabolic health. This combination works through multiple hormone pathways to help reduce hunger, regulate cravings, slow digestion, and promote lon Research use only — not for human or veterinary use.
Tap I use this — we'll set up your dose, reminders & journey in 30 seconds.
Retatrutide 20mg + Cagrilintide 5mg Retatrutide combined with Cagrilintide represents an advanced next-generation peptide therapy researched for its potential role in weight management, appetite regulation, and metabolic health optimization. This powerful combination works through multiple hormone pathways to support reduced hunger, improved satiety, enhanced metabolic function, and sustainable weight loss support. Retatrutide is designed to target GLP-1, GIP, and glucagon receptors, helping regulate appetite, energy expenditure, and blood sugar balance. Cagrilintide, an amylin analog, further supports appetite control by slowing digestion and promoting longer-lasting feelings of fullness. Together, these compounds may create a comprehensive metabolic approach aimed at supporting greater weight management outcomes than single therapies alone. Due to growing interest in advanced obesity and metabolic therapies, the combination of Retatrutide and Cagrilintide has gained significant attention in wellness and clinical research communities. Ongoing studies continue to explore its long-term safety, effectiveness, and potential benefits for metabolic health, obesity management, and overall wellness support.
- Peptide
- Retatrutide
- Strength
- 25 mg
- Package
- 25mg × 10 vials
- Form
- vial
- Concentration
- 25mg × 10 vials
